0001209191-23-013836.txt : 20230228 0001209191-23-013836.hdr.sgml : 20230228 20230228181313 ACCESSION NUMBER: 0001209191-23-013836 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230224 FILED AS OF DATE: 20230228 DATE AS OF CHANGE: 20230228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Newton Charles W. CENTRAL INDEX KEY: 0001866219 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40502 FILM NUMBER: 23688230 MAIL ADDRESS: STREET 1: 46 FREDRICK AVENUE CITY: ATHERTON STATE: CA ZIP: 94027 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lyell Immunopharma, Inc. CENTRAL INDEX KEY: 0001806952 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 833006753 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 201 HASKINS WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650 695-0677 MAIL ADDRESS: STREET 1: 201 HASKINS WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-24 0 0001806952 Lyell Immunopharma, Inc. LYEL 0001866219 Newton Charles W. C/O LYELL IMMUNOPHARMA, INC. 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Financial Officer Common Stock 2941 D Option (right to buy) 2.13 2023-02-24 4 A 0 700000 0.00 A 2033-02-23 Common Stock 700000 700000 D Shares acquired on May 18, 2022 under the Issuer's 2021 Employee Stock Purchase Plan. 12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months. /s/ Hector Casab, as Attorney-in-Fact 2023-02-28